8-K/A: DNA X, Inc. Amends Filing, Addresses Nasdaq Listing

DNA X, Inc. has filed an amendment to its Form 8-K to update disclosures regarding its equity position and its efforts to meet Nasdaq Capital Market continued listing requirements.

Summary

• This filing is an amendment (Amendment No. 2) to a previous Form 8-K, specifically updating Item 3.02 concerning unregistered sales of equity securities and Item 8.01 regarding other events.
• On August 7, 2026, the Company sold 416,667 shares of Series B Preferred Stock for $2.5 million in cash.
• The Company believes this transaction, along with other adjustments, brings its pro forma stockholders' equity above the $2.5 million threshold required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1).
• A pro forma summary of stockholders' equity is provided, showing an estimated ending equity of $5,840 thousand as of August 7, 2026.
• The Company is awaiting formal confirmation from Nasdaq regarding compliance with the equity rule and will provide an update upon receipt.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic development, as the company appears to be addressing a critical listing requirement, though final confirmation is pending.

Positives

• Successfully sold the remaining 416,667 shares of Series B Preferred Stock, raising $2.5 million in cash.
• Pro forma stockholders' equity is estimated to exceed the $2.5 million requirement for Nasdaq Capital Market continued listing.
• The company is actively working to meet Nasdaq's continued listing requirements, demonstrating a proactive approach to maintaining its listing status.

Negatives

• The company is still awaiting Nasdaq's formal determination of compliance with the equity listing rule.
• The pro forma financial information is based on management's current estimates and assumptions and is presented for illustrative purposes only.
• The company has experienced net losses in Q1 2026 and projected losses for Q2 2026, although the recent financing aims to offset this.

Risks

• The primary risk is Nasdaq's potential determination that the Company does not meet the continued listing requirements.
• Forward-looking statements are subject to significant uncertainty and risk, as detailed in the company's other SEC filings.
• The company's ability to continue as a going concern may be impacted if it fails to meet listing requirements or secure future financing.

Future Outlook

The company is awaiting Nasdaq's formal determination regarding its compliance with the Equity Rule and intends to provide an update upon receipt. The pro forma financial information is for illustrative purposes and not indicative of future financial condition or results.

Management Comments

• The Company believes it has stockholders equity in excess of the $2.5 million stockholders equity requirement for continued listing on The Nasdaq Capital Market.
• The pro forma information is based on managements current estimates and assumptions, is presented for illustrative purposes only, and should not be regarded as indicative of the Companys future financial condition or results of operations.

Industry Context

StockSavvy.ai notes that maintaining a Nasdaq listing is crucial for many growth-stage technology companies like DNA X, Inc., as it provides access to capital markets and enhances credibility. Failure to meet listing requirements can lead to delisting, significantly impacting liquidity and investor confidence.

Stakeholder Impact

• Shareholders: Maintaining the Nasdaq listing is critical for share liquidity and investor confidence. Delisting could negatively impact share value.
• Creditors: Continued listing provides a more stable environment for debt obligations.
• Employees: A stable listing status supports employee morale and retention.

Next Steps

• Await Nasdaq's formal determination regarding compliance with the Equity Rule.
• Provide an update to the market upon receipt of Nasdaq's determination.

Key Dates

Recommendation

The filing addresses a critical near-term risk (Nasdaq delisting) by demonstrating a path to meeting equity requirements. However, the outcome is not yet confirmed by Nasdaq, and the company's underlying operational performance (indicated by net losses) still requires significant improvement. Therefore, a 'hold' position is warranted pending Nasdaq's decision and further operational progress.

Keywords

Nasdaq listing, Equity Rule, Series B Preferred Stock, Stockholders Equity, Capital Raise, Form 8-K/A, Financial Compliance